1. Tomophase Corporation

    0 Comments Leave a Comment

    1-15 of 31 1 2 »
    1. Mentioned In 31 Articles

    2. Beyond Better Clinical Care: Optical Coherence Tomography's Economic Impact

      Beyond Better Clinical Care: Optical Coherence Tomography's Economic Impact
      The optical coherence tomography (OCT) industry has grown dramatically in its first 25 years, and while the positive effects on patient clinical care are the most important measure of OCT's success, its contributions to the economy in jobs, tax receipts, and healthcare savings are also noteworthy. The field of optical coherence tomography (OCT) has grown dramatically since its discovery in the early 1990s. The commercialization and growth of OCT ...
      Read Full Article
    3. Optical Coherence Tomography Industry Has Provided Well Over 20,000 Person-Years of Direct Employment

      Optical Coherence Tomography Industry Has Provided Well Over 20,000 Person-Years of Direct Employment
      The field of Optical Coherence Tomography (OCT) has grown dramatically since its discovery in the early 1990s. The commercialization and growth of OCT which has occurred over the past 25 years has been highly impactful, scientifically, clinically, and economically. Many factors have helped drive this success starting with the clinical need for new cost-effective high-resolution minimally-invasive imaging solutions for various diagnostic and therapeutic applications. But equally important to this success ...
      Read Full Article
    4. First Human Clinical Images Available with OCTIS™ Thanks to Tomophase Corporation and the Thoraxklinik, University of Heidelberg

      First Human Clinical Images Available with OCTIS™ Thanks to Tomophase Corporation and the Thoraxklinik, University of Heidelberg
      ...emand for the OCT Imaging System. Examples of our tissue imaging results are available at www.tomophase.com . Tomophase Corporation, a leading developer of minimally invasive optical coherence tomography (OCT) tissue ima...
      Read Full Article
    5. Tomophase and MOSS, S.p.A. Expand OCTIS Technology Throughout Italy with New Distribution Agreement

      Tomophase and MOSS, S.p.A. Expand OCTIS Technology Throughout Italy with New Distribution Agreement
      ...emand for the OCT Imaging System. Examples of our tissue imaging results are available at www.tomophase.com . Tomophase Corporation, a leading developer of minimally invasive optical coherence tomography (OCT) tissue ima...
      Read Full Article
    6. Ophthalmic OCT Reaches $1 Billion Per Year: But Reimbursement Clampdown Clouds Future Innovation

      Ophthalmic OCT Reaches $1 Billion Per Year: But Reimbursement Clampdown Clouds Future Innovation
      Long gone are the days when a new medical product could be easily introduced based solely on improved patient outcomes. To optimize the probability of success, a new product will benefit from demonstrating that it can both improve patient outcomes and reduce CapX and OpX costs. To the extent the cost benefits are easily quantifiable the more likely the product will be a success.  To the clinical practice manager, an ...
      Read Full Article
    7. Integrated disease diagnosis and treatment system

      Integrated disease diagnosis and treatment system
      Designs, implementations, and techniques for optically measuring a sample and integrated systems that provide CT-scan, optical probing and therapy by electromagnetic radiation treatment (e.g. laser, RF, or microwave). Light at different wavelength bands may be used to detect different absorption features in the sample. Multiple light sources may be used including tunable lasers.
      Read Full Article
    8. Tomophase Announces First Sale of Its OCT Imaging System (OCTIS™) for Research Use to the University of Texas

      Tomophase Announces First Sale of Its OCT Imaging System (OCTIS™) for Research Use to the University of Texas
      ...elease Distribution at http://www.ereleases.com.   SOURCE Tomophase Corporation Tomophase Press Release - Tomophase Corporation, a leading developer of minimally invasive optical coherence tomography (OCT) tissue ima...
      Read Full Article
    9. 1-15 of 31 1 2 »
  1. Categories

    1. Applications:

      Art, Cardiology, Dentistry, Dermatology, Developmental Biology, Gastroenterology, Gynecology, Microscopy, NDE/NDT, Neurology, Oncology, Ophthalmology, Other Non-Medical, Otolaryngology, Pulmonology, Urology
    2. Business News:

      Acquisition, Clinical Trials, Funding, Other Business News, Partnership, Patents
    3. Technology:

      Broadband Sources, Probes, Tunable Sources
    4. Miscellaneous:

      Jobs & Studentships, Student Theses, Textbooks
  2. About Tomophase Corporation

    Tomophase Corporation

    Tomophase Corporation.  Pulmonary Systems.  Tomophase Corporation is a private company founded in 2003 with a goal of providing innovative solutions for unmet medical needs through the use of light-based imaging and therapy. Many major advances in medicine have been marked by the introduction of new medical imaging tools, such as computed tomography, magnetic resonance imaging, and positron emission tomography. We believe that a new breakthrough, one of similar magnitude, is now within our reach — the use of light in guiding us to new ways of diagnosing diseases and improving our lives.  Tomophase has developed and patented technology in the field of optical coherence tomography (OCT) which is capable of delivering high quality, high resolution cross-sectional tissue images in real-time. With the Tomophase technology, tissue structure can be observed up to 2-3 mm below the surface with remarkable clarity and without biopsy or the use of radiation, UV light or image contrast agents.   Our first proposed application of this innovative technology is in pulmonary medicine for the tomographic imaging of airways and pulmonary tissue. We believe the Tomophase OCT imaging system will allow clinicians, for the first time, to visualize such microanatomic features as airway epithelia, mucosa, smooth muscle layer both in-vivo and in-situ. This may facilitate or improve many of the interventional procedures and therapeutic approaches in pulmonology. Further development may also lead to tools for improving the management of lung cancer as well as applications in other fields of medicine.  We at Tomophase are dedicated to fulfilling light’s diagnostic potential through continued innovations,
    skilled management, close alliances with the medical community, and excellence in engineering.

    In April 2014, Tomophase Corp. was acquired by a Chinese company called Winstar, and is now named Tomophase Inc